Radiolabeled antibodies for therapy of infectious diseases

Microbiology Spectrum

Volumn 2, Issue 6, 2014, Pages

  Dadachova, Ekaterina ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; FUNGUS ANTIBODY; VIRUS ANTIBODY;

ANIMAL; CHEMISTRY; COMMUNICABLE DISEASES; HUMAN; IMMUNOLOGY; PROCEDURES; RADIOIMMUNOTHERAPY;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, FUNGAL; ANTIBODIES, VIRAL; COMMUNICABLE DISEASES; HUMANS; RADIOIMMUNOTHERAPY;

EID: 84957428369     PISSN: None     EISSN: 21650497     Source Type: Journal    
DOI: 10.1128/microbiolspec.aid-0023-2014     Document Type: Article

References (30)

1. Dadachova E, Nakouzi A, Bryan R, Casadevall A. 2003. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA 100:10942-10947.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530.
3. Larsen RA, Pappas PG, Perfect J, Aberg JA, Casadevall A, Cloud GA, James R, Filler S, Dismukes WE. 2005. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 49:952-958.
4. Rhodes JC, Wicker LS, Urba WJ. 1980. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect Immun 29:494-499.
5. Jiang Z, Bryan RA, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. 2012. Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice. Antimicrob Agents Chemother 56:552-554.
6. Pai MP, Sakoglu U, Peterson SL, Lyons CR, Sood R. 2009. Characterization of BBB permeability in a preclinical model of cryptococcal meningoencephalitis using magnetic resonance imaging. J Cereb Blood Flow Metab 29:545-553.
7. Bryan RA, Jiang Z, Howell RC, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. 2010. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J Infect Dis 202:633-637.
8. Clemons KV, Stevens DA. 1998. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 42:899-902.
9. Kakeya H, Miyazaki Y, Senda H, Senda H, Kobayashi T, Seki M, Izumikawa K, Yamamoto Y, Yanagihara K, Tashiro T, Kohno S. 2008. Efficacy of SPK-843, a novel polyene antifungal, in a murine model of systemic cryptococcosis. Antimicrob Agents Chemother 52:1871-1872.
10. Bicanic T, Muzoora C, Brouwer AE, Brouwer AE, Meintjes G, Longley N, Taseera K, Rebe K, Loyse A, Jarvis J, Bekker LG, Wood R, Limmathurotsakul D, Chierakul W, Stepniewska K, White NJ, Jaffar S, Harrison TS. 2009. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 49:702-709.
11. Bryan RA, Jiang Z, Huang X, Morgenstern A, Bruchertseifer F, Sellers R, Casadevall A, Dadachova E. 2009. Radioimmunotherapy is effective against a high infection burden of Cryptococcus neoformans in mice and does not select for radiation-resistant phenotypes in cryptococcal cells. Antimicrob Agents Chemother 53:1679-1682.
12. Bryan RA, Huang X, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. 2008. Radio-fungicidal effects of external gamma radiation and antibody-targeted beta and alpha radiation on Cryptococcus neoformans. Antimicrob Agents Chemother 52:2232-2235.
13. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, Mignogna G, Maras B, Colone M, Stringaro A, Zamboni S, Feizi T, Cassone A. 2009. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 4:e5392. doi:10.1371/journal.pone.0005392.
14. Rachini A, Pietrella D, Lupo P, Torosantucci A, Chiani P, Bromuro C, Proietti C, Bistoni F, Cassone A, Vecchiarelli A. 2007. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 75:5085-5094.
15. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, Rappuoli R, Cassone A. 2005. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202:597-606.
16. Guimaraes AJ, Frases S, Gomez FJ, Zancope-Oliveira RM, Nosanchuk JD. 2009. Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum. Infect Immun 77:1357-1367.
17. Nosanchuk JD, Casadevall A. 2006. Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother 50:3519-3528.
18. Bryan RA, Guimaraes AJ, Hopcraft S, Jiang Z, Bonilla K, Morgenstern A, Bruchertseifer F, Del Poeta M, Torosantucci A, Cassone A, Nosanchuk JD, Casadevall A, Dadachova E. 2012. Towards developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia 73:463-471.
19. Dadachova E, Burns T, Bryan RA, Apostolidis C, Brechbiel MW, Nosanchuk JD, Casadevall A, Pirofski L. 2004. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob Agents Chemother 48:1624-1629.
20. Rivera J, Nakouzi AS, Morgenstern A, Bruchertseifer F, Dadachova E, Casadevall A. 2009. Radiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax. Antimicrob Agents Chemother 53:4860-4868.
21. Rivera J, Morgenstern A, Bruchertseifer F, Kearney JF, Turnbough CL, Jr, Dadachova E, Casadevall A. 2014. Microbicidal power of alpha radiation in sterilizing germinating Bacillus anthracis spores. Antimicrob Agents Chemother 58:1813-1815.
22. Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, Gorny MK, Zolla-Pazner S, Casadevall A, Goldstein H. 2006. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med 3:e427. doi:10.1371/journal.pmed.0030427.
23. Ho DD, Moudgil T, Alam M. 1989. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 321:1621-1625.
24. Casadevall A, Goldstein H, Dadachova E. 2007. Targeting virusesharboring host cells with radiolabeled antibodies. Expert Opin Biol Ther 7:595-597.
25. Dadachova E, Kitchen SG, Bristol G, Baldwin GC, Revskaya E, Empig C, Thornton GB, Gorny MK, Zolla-Pazner S, Casadevall A. 2012. Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. PLoS One 7:e31866. doi:10.1371/journal.pone.0031866.
26. Mosier DE. 1996. Viral pathogenesis in hu-PBL-SCID mice. Sem Immunol 8:255-262.
27. Gigler A, Dorsch S, Hemauer A, Williams C, Kim S. 1999. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 73:1974-1979.
28. Milenic DE, Brady ED, Brechbiel MW. 2004. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3:488-499.
29. Uckun FM, Rajamohan F, Pendergrass S, Ozer Z, Waurzyniak B, Mao C. 2003. Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent-anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 47:1052-1061.
30. Uckun FM, Qazi S, Pendergrass S, Lisowski E, Waurzyniak B, Chen CL, Venkatachalam TK. 2002. In vivo toxicity, pharmacokinetics, and antihuman immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) stampidine in mice. Antimicrob Agents Chemother 46:3428-3436.